Peter Greenleaf
2014 - Sucampo Pharmaceuticals
In 2014, Peter Greenleaf earned a total compensation of $5.7M as Chief Executive Officer and Chairman of the Board of Directors at Sucampo Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $369,762 |
|---|---|
| Option Awards | $4,838,780 |
| Salary | $440,192 |
| Other | $2,025 |
| Total | $5,650,759 |
Greenleaf received $4.8M in option awards, accounting for 86% of the total pay in 2014.
Greenleaf also received $369.8K in non-equity incentive plan, $440.2K in salary and $2K in other compensation.
Rankings
In 2014, Peter Greenleaf's compensation ranked 1,300th out of 13,032 executives tracked by ExecPay. In other words, Greenleaf earned more than 90.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,300 out of 13,032 | 90th |
Division Manufacturing | 475 out of 4,965 | 90th |
Major group Chemicals And Allied Products | 150 out of 1,690 | 91st |
Industry group Drugs | 118 out of 1,369 | 91st |
Industry Pharmaceutical Preparations | 103 out of 1,042 | 90th |
Source: SEC filing on April 21, 2017.
Greenleaf's colleagues
We found five more compensation records of executives who worked with Peter Greenleaf at Sucampo Pharmaceuticals in 2014.
2014
Peter Kiener
Sucampo Pharmaceuticals
Chief Scientific Officer
2014
Matthias Alder
Sucampo Pharmaceuticals
General Counsel
2014
Max Donley
Sucampo Pharmaceuticals
EVP, Global Human Resources, Information Technology and Strategy
2014
Peter Lichtlen
Sucampo Pharmaceuticals
Chief Medical Officer
2014
Andrew Smith
Sucampo Pharmaceuticals
Chief Financial Officer
News
Aurinia Pharmaceuticals CEO Peter Greenleaf's 2021 pay falls 88% to $1.2M
April 18, 2022
Aurinia Pharmaceuticals CEO Peter Greenleaf's 2020 pay jumps 1,353% to $11M
May 10, 2021
Avalo Therapeutics Chairman Simon Pedder's 2019 pay jumps 13,562% to $3.8M
April 28, 2020
Avalo Therapeutics CEO Peter Greenleaf's 2018 pay jumps 17,372% to $5.1M
June 19, 2019